Login
Sign Up
Login
Sign Up
Features
Pricing
Reg.News
Contact
Login
Sign Up
Search
Providers
Companies
⨯
LIVE
Event in Progress:
Join Here
×
Search
Providers
Companies
⨯
Features
Pricing
Event Hub
Reg.News
Short Interest
Contact
All the news articles and press releases in one place.
UK Reg. News
German Reg. News
Search
Key Announcements
Results / Trading Updates
Get free RNS email alerts for@Model.CurrentFilterValue
Currently filtered for Faron Pharmaceuticals Oy
Clear Filter
Sector
Automobile Industry
Banks
Basic Materials
Building & Construction
Chemicals
Consumer Discretionary Goods
Consumer Discretionary Services
Consumer Staple Goods
Consumer Staple Services
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Finance
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Market Cap
Below £20m
£20m - £100m
£100m - £300m
£300m - £1bn
£1bn - £10bn
Over £10bn
Filters »
All
UK100
UK250
UK SmallCap
UK Other
Show:
10
25
50
100
«
1
2
3
4
»
Date / Time
Source
Ticker
Company
Sector
Market Cap
Announcement
05May20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Clevegen manufacturing agreement
29Apr20 13:15
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
27Apr20 14:45
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
27Apr20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Traumakine to be a part of WHO’s Solidarity trial
23Apr20 13:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Update on results of Placing and issue of equity
22Apr20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Result of placing and issue price
21Apr20 16:45
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Proposed Placing
14Apr20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Notice of Annual General Meeting
03Apr20 14:45
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
AGM to be postponed
01Apr20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
REMAP-CAP to study IFN beta-1a effect in COVID-19
30Mar20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Part 1 of the MATINS Phase I/II Study Completed
26Mar20 10:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Correction to Faron´s Annual Report 2019
25Mar20 07:28
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron´s Annual Report 2019 published
20Mar20 11:30
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Notice of Annual General Meeting
20Mar20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Final Results for the year ended December 31, 2019
09Mar20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
FDA accepts protocol for new Traumakine trial
05Mar20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
MATINS update
02Mar20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron to acquire AOC3 antagonist platform
06Feb20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Traumakine update
27Jan20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Ovarian cancer selected as 2nd MATINS trial cohort
13Jan20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
DMC approves colorectal cancer cohort expansion
30Dec19 09:30
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Update on Traumakine drug substance manufacturing
11Dec19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Matins Trial Update
29Nov19 07:31
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
LIQUIDITY PROVIDING AGREEMENT
29Nov19 07:30
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Company Description & information on cash position
28Nov19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
FDA has approved Faron's Clevegen IND
27Nov19 16:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron´s financial calendar for 2020
21Nov19 14:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holdings in Company
21Nov19 07:15
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Application to Nasdaq First North Growth Market
12Nov19 15:45
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Registration of Shares
08Nov19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Results of Placing and Issue Price
07Nov19 16:51
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Proposed Placing and Financial Adviser Appointment
01Nov19 14:15
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Statement regarding Price Movement
25Oct19 09:27
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Results of EGM
09Oct19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Matins Trial Update
04Oct19 07:20
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Notice of EGM
02Oct19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Update on Traumakine drug substance manufacturing
30Sep19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
MATINS poster presentation at ESMO Congress
25Sep19 09:13
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holdings in Company
23Sep19 07:08
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Interim results
02Sep19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
MATINS study selected for ESMO 2019
27Aug19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Result of Open Offer and Further Subscription
19Aug19 09:33
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
16Aug19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Notice of Interim Results
06Aug19 13:53
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Issue of Equity
05Aug19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Subscription and Open Offer
12Jul19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
MATINS study update
04Jul19 09:31
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holdings in Company
01Jul19 12:10
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Grant of options
26Jun19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Phase II INFORAAA study update
14Jun19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Final results from YODA study
28May19 12:27
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Results of AGM
24May19 09:32
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
AGM update, Board & management changes
22May19 12:51
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Grant of Options
21May19 09:21
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
16May19 09:16
RNS
FARN:LON, AV:LON
Aviva plc, Faron Pharmaceuticals Oy
Various
Various
Holding(s) in Company
14May19 07:01
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holdings in Company
14May19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Share Subscription and Issue of Equity
07May19 07:05
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Notice of AGM
07May19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Final Results for the year ended 31 December 2018
02May19 17:20
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Statement regarding Price Movement
29Apr19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Results from the Japanese Phase III study
25Apr19 16:09
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
12Apr19 13:20
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
11Apr19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
First expansion cohort for MATINS trial part 2
10Apr19 11:41
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
05Apr19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Notice of Results
02Apr19 09:23
RNS
FARN:LON, AV:LON
Aviva plc, Faron Pharmaceuticals Oy
Various
Various
Holdings in Company
29Mar19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
28Mar19 12:54
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Results of the Placing and Subscription
26Mar19 15:31
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Result of Placing and Issue Price
26Mar19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Proposed Placing to raise approximately EUR 3m
21Feb19 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
MATINS study update
13Feb19 08:57
RNS-R
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
New data published by Clinical Cancer Research
19Dec18 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Traumakine update - YODA results
14Dec18 11:20
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
First patient dosed in phase I/II MATINS study
11Dec18 16:26
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
05Dec18 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Patient subgroup identified from INTEREST trial
03Dec18 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron receives CTA approval for Clevegen
06Nov18 15:52
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
PDMR Dealings
22Oct18 15:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
INTEREST trial update presented at ESICM
18Sep18 09:23
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Director/PDMR Shareholding
17Sep18 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron announces CTA filing for Clevegen
13Sep18 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Interim Results
08Aug18 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Notice of Interim Results
09Jul18 08:45
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
22Jun18 07:00
RNS
FARN:LON, LGEN:LON
Faron Pharmaceuticals Oy, Legal & General Group Plc
Various
Various
Holdings in Company
21Jun18 15:58
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Director/PDMR Shareholding
21Jun18 07:40
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Director/PDMR Shareholding
20Jun18 08:43
RNS
FARN:LON, LGEN:LON
Faron Pharmaceuticals Oy, Legal & General Group Plc
Various
Various
Holding(s) in Company
18Jun18 15:42
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holdings in Company
14Jun18 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Biomarker analysis of Phase III INTEREST trial
31May18 14:33
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Result of AGM
16May18 17:53
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
PDMR Shareholding
15May18 15:14
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Director/PDMR Shareholding
15May18 13:16
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holdings in Company
11May18 16:51
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
11May18 13:37
RNS
FARN:LON, LGEN:LON
Faron Pharmaceuticals Oy, Legal & General Group Plc
Various
Various
Holding(s) in Company
11May18 13:34
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
10May18 10:05
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Notice of AGM
«
1
2
3
4
»
Date / Time
Source
Company
% Chg
05May20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Clevegen manufacturing agreement
29Apr20 13:15
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
27Apr20 14:45
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
27Apr20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Traumakine to be a part of WHO’s Solidarity trial
23Apr20 13:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Update on results of Placing and issue of equity
22Apr20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Result of placing and issue price
21Apr20 16:45
RNS
Faron Pharmaceuticals Oy
-0.42%
Proposed Placing
14Apr20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Notice of Annual General Meeting
03Apr20 14:45
RNS
Faron Pharmaceuticals Oy
-0.42%
AGM to be postponed
01Apr20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
REMAP-CAP to study IFN beta-1a effect in COVID-19
30Mar20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Part 1 of the MATINS Phase I/II Study Completed
26Mar20 10:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Correction to Faron´s Annual Report 2019
25Mar20 07:28
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron´s Annual Report 2019 published
20Mar20 11:30
RNS
Faron Pharmaceuticals Oy
-0.42%
Notice of Annual General Meeting
20Mar20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Final Results for the year ended December 31, 2019
09Mar20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
FDA accepts protocol for new Traumakine trial
05Mar20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
MATINS update
02Mar20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron to acquire AOC3 antagonist platform
06Feb20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Traumakine update
27Jan20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Ovarian cancer selected as 2nd MATINS trial cohort
13Jan20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
DMC approves colorectal cancer cohort expansion
30Dec19 09:30
RNS
Faron Pharmaceuticals Oy
-0.42%
Update on Traumakine drug substance manufacturing
11Dec19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Matins Trial Update
29Nov19 07:31
RNS
Faron Pharmaceuticals Oy
-0.42%
LIQUIDITY PROVIDING AGREEMENT
29Nov19 07:30
RNS
Faron Pharmaceuticals Oy
-0.42%
Company Description & information on cash position
28Nov19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
FDA has approved Faron's Clevegen IND
27Nov19 16:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron´s financial calendar for 2020
21Nov19 14:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Holdings in Company
21Nov19 07:15
RNS
Faron Pharmaceuticals Oy
-0.42%
Application to Nasdaq First North Growth Market
12Nov19 15:45
RNS
Faron Pharmaceuticals Oy
-0.42%
Registration of Shares
08Nov19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Results of Placing and Issue Price
07Nov19 16:51
RNS
Faron Pharmaceuticals Oy
-0.42%
Proposed Placing and Financial Adviser Appointment
01Nov19 14:15
RNS
Faron Pharmaceuticals Oy
-0.42%
Statement regarding Price Movement
25Oct19 09:27
RNS
Faron Pharmaceuticals Oy
-0.42%
Results of EGM
09Oct19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Matins Trial Update
04Oct19 07:20
RNS
Faron Pharmaceuticals Oy
-0.42%
Notice of EGM
02Oct19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Update on Traumakine drug substance manufacturing
30Sep19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
MATINS poster presentation at ESMO Congress
25Sep19 09:13
RNS
Faron Pharmaceuticals Oy
-0.42%
Holdings in Company
23Sep19 07:08
RNS
Faron Pharmaceuticals Oy
-0.42%
Interim results
02Sep19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
MATINS study selected for ESMO 2019
27Aug19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Result of Open Offer and Further Subscription
19Aug19 09:33
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
16Aug19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Notice of Interim Results
06Aug19 13:53
RNS
Faron Pharmaceuticals Oy
-0.42%
Issue of Equity
05Aug19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Subscription and Open Offer
12Jul19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
MATINS study update
04Jul19 09:31
RNS
Faron Pharmaceuticals Oy
-0.42%
Holdings in Company
01Jul19 12:10
RNS
Faron Pharmaceuticals Oy
-0.42%
Grant of options
26Jun19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Phase II INFORAAA study update
14Jun19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Final results from YODA study
28May19 12:27
RNS
Faron Pharmaceuticals Oy
-0.42%
Results of AGM
24May19 09:32
RNS
Faron Pharmaceuticals Oy
-0.42%
AGM update, Board & management changes
22May19 12:51
RNS
Faron Pharmaceuticals Oy
-0.42%
Grant of Options
21May19 09:21
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
16May19 09:16
RNS
Aviva plc, Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
14May19 07:01
RNS
Faron Pharmaceuticals Oy
-0.42%
Holdings in Company
14May19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Share Subscription and Issue of Equity
07May19 07:05
RNS
Faron Pharmaceuticals Oy
-0.42%
Notice of AGM
07May19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Final Results for the year ended 31 December 2018
02May19 17:20
RNS
Faron Pharmaceuticals Oy
-0.42%
Statement regarding Price Movement
29Apr19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Results from the Japanese Phase III study
25Apr19 16:09
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
12Apr19 13:20
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
11Apr19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
First expansion cohort for MATINS trial part 2
10Apr19 11:41
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
05Apr19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Notice of Results
02Apr19 09:23
RNS
Aviva plc, Faron Pharmaceuticals Oy
-0.42%
Holdings in Company
29Mar19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
28Mar19 12:54
RNS
Faron Pharmaceuticals Oy
-0.42%
Results of the Placing and Subscription
26Mar19 15:31
RNS
Faron Pharmaceuticals Oy
-0.42%
Result of Placing and Issue Price
26Mar19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Proposed Placing to raise approximately EUR 3m
21Feb19 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
MATINS study update
13Feb19 08:57
RNS-R
Faron Pharmaceuticals Oy
-0.42%
New data published by Clinical Cancer Research
19Dec18 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Traumakine update - YODA results
14Dec18 11:20
RNS
Faron Pharmaceuticals Oy
-0.42%
First patient dosed in phase I/II MATINS study
11Dec18 16:26
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
05Dec18 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Patient subgroup identified from INTEREST trial
03Dec18 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron receives CTA approval for Clevegen
06Nov18 15:52
RNS
Faron Pharmaceuticals Oy
-0.42%
PDMR Dealings
22Oct18 15:00
RNS
Faron Pharmaceuticals Oy
-0.42%
INTEREST trial update presented at ESICM
18Sep18 09:23
RNS
Faron Pharmaceuticals Oy
-0.42%
Director/PDMR Shareholding
17Sep18 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron announces CTA filing for Clevegen
13Sep18 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Interim Results
08Aug18 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Notice of Interim Results
09Jul18 08:45
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
22Jun18 07:00
RNS
Faron Pharmaceuticals Oy, Legal & General Group Plc
-0.42%
Holdings in Company
21Jun18 15:58
RNS
Faron Pharmaceuticals Oy
-0.42%
Director/PDMR Shareholding
21Jun18 07:40
RNS
Faron Pharmaceuticals Oy
-0.42%
Director/PDMR Shareholding
20Jun18 08:43
RNS
Faron Pharmaceuticals Oy, Legal & General Group Plc
-0.42%
Holding(s) in Company
18Jun18 15:42
RNS
Faron Pharmaceuticals Oy
-0.42%
Holdings in Company
14Jun18 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Biomarker analysis of Phase III INTEREST trial
31May18 14:33
RNS
Faron Pharmaceuticals Oy
-0.42%
Result of AGM
16May18 17:53
RNS
Faron Pharmaceuticals Oy
-0.42%
PDMR Shareholding
15May18 15:14
RNS
Faron Pharmaceuticals Oy
-0.42%
Director/PDMR Shareholding
15May18 13:16
RNS
Faron Pharmaceuticals Oy
-0.42%
Holdings in Company
11May18 16:51
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
11May18 13:37
RNS
Faron Pharmaceuticals Oy, Legal & General Group Plc
-0.42%
Holding(s) in Company
11May18 13:34
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
10May18 10:05
RNS
Faron Pharmaceuticals Oy
-0.42%
Notice of AGM
«
1
2
3
4
»
Date / Time
Company
% Chg
05May20 07:00
Faron Pharmaceuticals Oy
-0.42%
Clevegen manufacturing agreement
29Apr20 13:15
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
27Apr20 14:45
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
27Apr20 07:00
Faron Pharmaceuticals Oy
-0.42%
Traumakine to be a part of WHO’s Solidarity trial
23Apr20 13:00
Faron Pharmaceuticals Oy
-0.42%
Update on results of Placing and issue of equity
22Apr20 07:00
Faron Pharmaceuticals Oy
-0.42%
Result of placing and issue price
21Apr20 16:45
Faron Pharmaceuticals Oy
-0.42%
Proposed Placing
14Apr20 07:00
Faron Pharmaceuticals Oy
-0.42%
Notice of Annual General Meeting
03Apr20 14:45
Faron Pharmaceuticals Oy
-0.42%
AGM to be postponed
01Apr20 07:00
Faron Pharmaceuticals Oy
-0.42%
REMAP-CAP to study IFN beta-1a effect in COVID-19
30Mar20 07:00
Faron Pharmaceuticals Oy
-0.42%
Part 1 of the MATINS Phase I/II Study Completed
26Mar20 10:00
Faron Pharmaceuticals Oy
-0.42%
Correction to Faron´s Annual Report 2019
25Mar20 07:28
Faron Pharmaceuticals Oy
-0.42%
Faron´s Annual Report 2019 published
20Mar20 11:30
Faron Pharmaceuticals Oy
-0.42%
Notice of Annual General Meeting
20Mar20 07:00
Faron Pharmaceuticals Oy
-0.42%
Final Results for the year ended December 31, 2019
09Mar20 07:00
Faron Pharmaceuticals Oy
-0.42%
FDA accepts protocol for new Traumakine trial
05Mar20 07:00
Faron Pharmaceuticals Oy
-0.42%
MATINS update
02Mar20 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron to acquire AOC3 antagonist platform
06Feb20 07:00
Faron Pharmaceuticals Oy
-0.42%
Traumakine update
27Jan20 07:00
Faron Pharmaceuticals Oy
-0.42%
Ovarian cancer selected as 2nd MATINS trial cohort
13Jan20 07:00
Faron Pharmaceuticals Oy
-0.42%
DMC approves colorectal cancer cohort expansion
30Dec19 09:30
Faron Pharmaceuticals Oy
-0.42%
Update on Traumakine drug substance manufacturing
11Dec19 07:00
Faron Pharmaceuticals Oy
-0.42%
Matins Trial Update
29Nov19 07:31
Faron Pharmaceuticals Oy
-0.42%
LIQUIDITY PROVIDING AGREEMENT
29Nov19 07:30
Faron Pharmaceuticals Oy
-0.42%
Company Description & information on cash position
28Nov19 07:00
Faron Pharmaceuticals Oy
-0.42%
FDA has approved Faron's Clevegen IND
27Nov19 16:00
Faron Pharmaceuticals Oy
-0.42%
Faron´s financial calendar for 2020
21Nov19 14:00
Faron Pharmaceuticals Oy
-0.42%
Holdings in Company
21Nov19 07:15
Faron Pharmaceuticals Oy
-0.42%
Application to Nasdaq First North Growth Market
12Nov19 15:45
Faron Pharmaceuticals Oy
-0.42%
Registration of Shares
08Nov19 07:00
Faron Pharmaceuticals Oy
-0.42%
Results of Placing and Issue Price
07Nov19 16:51
Faron Pharmaceuticals Oy
-0.42%
Proposed Placing and Financial Adviser Appointment
01Nov19 14:15
Faron Pharmaceuticals Oy
-0.42%
Statement regarding Price Movement
25Oct19 09:27
Faron Pharmaceuticals Oy
-0.42%
Results of EGM
09Oct19 07:00
Faron Pharmaceuticals Oy
-0.42%
Matins Trial Update
04Oct19 07:20
Faron Pharmaceuticals Oy
-0.42%
Notice of EGM
02Oct19 07:00
Faron Pharmaceuticals Oy
-0.42%
Update on Traumakine drug substance manufacturing
30Sep19 07:00
Faron Pharmaceuticals Oy
-0.42%
MATINS poster presentation at ESMO Congress
25Sep19 09:13
Faron Pharmaceuticals Oy
-0.42%
Holdings in Company
23Sep19 07:08
Faron Pharmaceuticals Oy
-0.42%
Interim results
02Sep19 07:00
Faron Pharmaceuticals Oy
-0.42%
MATINS study selected for ESMO 2019
27Aug19 07:00
Faron Pharmaceuticals Oy
-0.42%
Result of Open Offer and Further Subscription
19Aug19 09:33
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
16Aug19 07:00
Faron Pharmaceuticals Oy
-0.42%
Notice of Interim Results
06Aug19 13:53
Faron Pharmaceuticals Oy
-0.42%
Issue of Equity
05Aug19 07:00
Faron Pharmaceuticals Oy
-0.42%
Subscription and Open Offer
12Jul19 07:00
Faron Pharmaceuticals Oy
-0.42%
MATINS study update
04Jul19 09:31
Faron Pharmaceuticals Oy
-0.42%
Holdings in Company
01Jul19 12:10
Faron Pharmaceuticals Oy
-0.42%
Grant of options
26Jun19 07:00
Faron Pharmaceuticals Oy
-0.42%
Phase II INFORAAA study update
14Jun19 07:00
Faron Pharmaceuticals Oy
-0.42%
Final results from YODA study
28May19 12:27
Faron Pharmaceuticals Oy
-0.42%
Results of AGM
24May19 09:32
Faron Pharmaceuticals Oy
-0.42%
AGM update, Board & management changes
22May19 12:51
Faron Pharmaceuticals Oy
-0.42%
Grant of Options
21May19 09:21
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
16May19 09:16
AV. LSE,FARN LSE
-0.42%
Holding(s) in Company
14May19 07:01
Faron Pharmaceuticals Oy
-0.42%
Holdings in Company
14May19 07:00
Faron Pharmaceuticals Oy
-0.42%
Share Subscription and Issue of Equity
07May19 07:05
Faron Pharmaceuticals Oy
-0.42%
Notice of AGM
07May19 07:00
Faron Pharmaceuticals Oy
-0.42%
Final Results for the year ended 31 December 2018
02May19 17:20
Faron Pharmaceuticals Oy
-0.42%
Statement regarding Price Movement
29Apr19 07:00
Faron Pharmaceuticals Oy
-0.42%
Results from the Japanese Phase III study
25Apr19 16:09
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
12Apr19 13:20
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
11Apr19 07:00
Faron Pharmaceuticals Oy
-0.42%
First expansion cohort for MATINS trial part 2
10Apr19 11:41
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
05Apr19 07:00
Faron Pharmaceuticals Oy
-0.42%
Notice of Results
02Apr19 09:23
AV. LSE,FARN LSE
-0.42%
Holdings in Company
29Mar19 07:00
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
28Mar19 12:54
Faron Pharmaceuticals Oy
-0.42%
Results of the Placing and Subscription
26Mar19 15:31
Faron Pharmaceuticals Oy
-0.42%
Result of Placing and Issue Price
26Mar19 07:00
Faron Pharmaceuticals Oy
-0.42%
Proposed Placing to raise approximately EUR 3m
21Feb19 07:00
Faron Pharmaceuticals Oy
-0.42%
MATINS study update
13Feb19 08:57
Faron Pharmaceuticals Oy
-0.42%
New data published by Clinical Cancer Research
19Dec18 07:00
Faron Pharmaceuticals Oy
-0.42%
Traumakine update - YODA results
14Dec18 11:20
Faron Pharmaceuticals Oy
-0.42%
First patient dosed in phase I/II MATINS study
11Dec18 16:26
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
05Dec18 07:00
Faron Pharmaceuticals Oy
-0.42%
Patient subgroup identified from INTEREST trial
03Dec18 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron receives CTA approval for Clevegen
06Nov18 15:52
Faron Pharmaceuticals Oy
-0.42%
PDMR Dealings
22Oct18 15:00
Faron Pharmaceuticals Oy
-0.42%
INTEREST trial update presented at ESICM
18Sep18 09:23
Faron Pharmaceuticals Oy
-0.42%
Director/PDMR Shareholding
17Sep18 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron announces CTA filing for Clevegen
13Sep18 07:00
Faron Pharmaceuticals Oy
-0.42%
Interim Results
08Aug18 07:00
Faron Pharmaceuticals Oy
-0.42%
Notice of Interim Results
09Jul18 08:45
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
22Jun18 07:00
FARN LSE,LGEN LSE
-0.42%
Holdings in Company
21Jun18 15:58
Faron Pharmaceuticals Oy
-0.42%
Director/PDMR Shareholding
21Jun18 07:40
Faron Pharmaceuticals Oy
-0.42%
Director/PDMR Shareholding
20Jun18 08:43
FARN LSE,LGEN LSE
-0.42%
Holding(s) in Company
18Jun18 15:42
Faron Pharmaceuticals Oy
-0.42%
Holdings in Company
14Jun18 07:00
Faron Pharmaceuticals Oy
-0.42%
Biomarker analysis of Phase III INTEREST trial
31May18 14:33
Faron Pharmaceuticals Oy
-0.42%
Result of AGM
16May18 17:53
Faron Pharmaceuticals Oy
-0.42%
PDMR Shareholding
15May18 15:14
Faron Pharmaceuticals Oy
-0.42%
Director/PDMR Shareholding
15May18 13:16
Faron Pharmaceuticals Oy
-0.42%
Holdings in Company
11May18 16:51
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
11May18 13:37
FARN LSE,LGEN LSE
-0.42%
Holding(s) in Company
11May18 13:34
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
10May18 10:05
Faron Pharmaceuticals Oy
-0.42%
Notice of AGM
«
1
2
3
4
»
Strapline
Strapline
Question 1
Answer 1
Question 2
Answer 2
Question 3
Answer 3
Question 4
Answer 4
Question 5
Answer 5
Question 6
Answer 6
Question 7
Answer 7
Question 8
Answer 8
Top
Home
Features
Pricing
Event Hub
Reg.News
Short Interest Tracker
Explore Content
Regions
UK
Rest of EMEA
N America
APAC
LatAm
Exchanges
Aquis Apex
Australian Securities Exchange
Canadian Securities Exchange
Euronext Paris
London Stock Exchange (domestic)
SIX Swiss Exchange
Sectors
Automobile Industry
Banks
Building & Construction
Chemicals
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Utilities
Small / Large Cap
UK100
UK250
UK Smallcap
UK Other Main Markets
Other
Private/EIS
EIS Single Company
EIS/SEIS Funds
IHT Products
SEIS Single Company
VCT Funds
Providers
Free/Commissioned
ACF Equity Research
Actio Advisors
Align Research
Atrium Research
BlytheRay
BNP Paribas Exane - Sponsored Research
Brand Communications
BRR Media
Calvine Partners
Capital Access Group
Capital Markets Brokers
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Edison
Equity Development
eResearch
Fidante Partners
Five Minute Pitch TV
focusIR
Fundamental Research Corp
Galliano’s Latin Notes
goetzpartners securities Limited
H2 Radnor
Hardman & Co
Holland Advisors
Hypothesis Research
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Magnitogorsk Iron and steel works
Mello Events
Mining Network
NuWays
Paul Scott
Peel Hunt
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Resolve Research
SEAL Advisors Ltd
ShareSoc
Shore Capital
Small Cap Consumer Research LLC
StockBox
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
Turner Pope Investments
UK Investor Group
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
High Net Worth Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane - Sponsored Research
Canaccord Genuity
Cavendish
Couloir Capital
Dowgate Capital
First Berlin
First Sentinel
GSBR Research
Hannam & Partners
Hybridan
Kemeny Capital
Liberum
Longspur Clean Energy
Louis Capital
Magnitogorsk Iron and steel works
Medley Global Advisors
Northland Capital Partners
QuotedData Professional
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
Tennyson Securities
The Life Sciences Division
Turner Pope Investments
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Institutional Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
BNP Paribas Exane
BRR Media
Calvine Partners
Canaccord Genuity
Capital Access Group
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Dowgate Capital
Edison
Equity Development
eResearch
Fidante Partners
First Berlin
First Sentinel
Five Minute Pitch TV
Fundamental Research Corp
Galliano’s Latin Notes
Goodbody
H2 Radnor
Hannam & Partners
Hardman & Co
Holland Advisors
Hybridan
Inbound Capital
Independent Investment Research
InterAxS Global
Investec Bank
Kemeny Capital
Kepler | Absolute Hedge
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Longspur Clean Energy
Magnitogorsk Iron and steel works
Mello Events
Mining Network
Northland Capital Partners
Numis
NuWays
Panmure Gordon
Peel Hunt
piworld.co.uk
Proactive
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
Small Cap Consumer Research LLC
SP Angel
Stanford Capital Partners
Stifel
StockBox
Tamesis Partners
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
UK Investor Group
Velocity Trade
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
Contact
Sign Up
Sign In
Share: